Instant Access to Deep Knowledge on Pharmaceutical Drugs

Core Data

$2995/year

► Instant Access

Inquire about site licenses
-
-
-
-
-
-
US & International Patent Data
Detailed Regulatory Status
Email Alerts and Data Export
 More Comprehensive

Patents Plus

$3995/year

► Instant Access

Inquire about site licenses
-
-
-
Expired Patents
Non-Orange Book Patents
Finished Product Suppliers
US & International Patent Data
Detailed Regulatory Status
Email Alerts and Data Export
 Most Comprehensive

Forecasting

$7995/year

► Instant Access

Inquire about site licenses
Clinical Trials
Bulk API Vendors
Formulation and Manufacturing
Expired Patents
Non-Orange Book Patents
Finished Product Suppliers
US & International Patent Data
Detailed Regulatory Status
Email Alerts and Data Export

Request a Callback

Name: *
Email: *
Company: *
Telephone: *
Message:

Pick Your Plan

 More Comprehensive  Most Comprehensive
Feature Core Data Patents Plus Forecasting Plan
Patents
Detailed Patent Information
International Patent Data
Supplementary Protection Certificates (SPCs)
Non-Orange Book Patents -
Expired Patents (1986 - Present) -
Regulatory
Detailed Regulatory Status
Paragraph IV Challenges
Tentative Approvals (indicates impending generic entry)
Drug Master File Listings
Authorized Generics -
Drug Information
Comprehensive Drug Information
Drug Class
Suppliers -
Bulk API Vendors - -
Formulation - -
Manufacturing - -
Additional Features
Email Alerts
Data Export
Dynamic Trend Graphs
Price / Year $2995 $3995 $7995
► INSTANT ACCESS
Inquire about site licenses
► INSTANT ACCESS
Inquire about site licenses
► INSTANT ACCESS
Inquire about site licenses

Frequently Asked Questions

DrugPatentWatch has patent coverage for the following countries and regional organizations:

African Intellectual Property Organization (OAPI) African Regional IP Organization (ARIPO) Algeria Argentina Australia Austria Bahrain (GCC) Belgium Benin (OAPI) Bosnia and Herzegovina Botswana (ARIPO) Brazil Bulgaria Burkina Faso (OAPI) Cameroon (OAPI) Canada Central African Republic (OAPI) Chad (OAPI) Chile China Colombia Comoros (OAPI) Congo-Brazzaville (OAPI) Costa Rica Croatia Cuba Cyprus Czech Republic Czechoslovakia Côte d'Ivoire (OAPI) Denmark Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea (OAPI) Estonia Eurasian Patent Organization European Patent Office Finland France Gabon (OAPI) Georgia, Republic of German Democratic Republic Germany Ghana (ARIPO) Greece Guatemala Guinea (OAPI) Guinea-Bissau (OAPI) Gulf Cooperation Council Honduras Hong Kong Hungary Iceland India Indonesia Ireland Israel Italy Japan Jordan Kenya (ARIPO) Kuwait (GCC) Latvia Lesotho (ARIPO) Liberia (ARIPO) Lithuania Luxembourg Malawi (ARIPO) Malaysia Mali (OAPI) Mauritania (OAPI) Mexico Moldova, Republic of Monaco Montenegro Morocco Mozambique (ARIPO) Namibia (ARIPO) Netherlands New Zealand Nicaragua Niger (OAPI) Norway Oman (GCC) Panama Peru Philippines Poland Portugal Qatar (GCC) Romania Russian Federation Rwanda (ARIPO) San Marino Saudi Arabia (GCC) Senegal (OAPI) Serbia Sierra Leone (ARIPO) Singapore Slovakia Slovenia Somalia (ARIPO) South Africa South Korea Spain Sudan (ARIPO) Swaziland (ARIPO) Sweden Switzerland São Tomé and Príncipe (ARIPO) Taiwan Tajikistan Tanzania (ARIPO) The Gambia (ARIPO) Togo (OAPI) Tunisia Turkey Uganda (ARIPO) Ukraine United Arab Emirates (GCC) United Kingdom United States of America Uruguay Viet Nam Yugoslavia Zambia (ARIPO) Zimbabwe (ARIPO)

Adding an alert is as easy as clicking the 'Add Alert' button on a page of interest.

    Available alerts include:

  • Paragraph IV challenges
  • New drugs and added or expired patents per company
  • Added or expired patents per drug
  • Tentative approvals

The Enterprise Plan enables unlimited users (identified by IP blocks), within your organization. The Single User plans cannot be shared, but multiple accounts can be purchased for a substantial discount.

Please use the contact form and tell us which subscription plan you would like an invoice for.

No problem. Please use the contact form and let us know how we can be of assistance.

Trusted by Industry Leaders

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Fortune- Generics' new legal attack: Big Pharma's aging patents CNN Money - Generics' new legal attack: Big Pharma's aging patents New England Journal of Medicine Barrons

Globalization of Pharmaceutical Drug Innovation The structure and business of biopharmaceutical companies including the management of risks and resources Drug Topics Nature Biotechnology Business Insider National Bureau of Economic Research

For more information try a trial or see the database preview.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc